Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: CNS Pharmaceuticals Inc. CNSP

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Patient Enrollment in Berubicin Study

Posted on May 19, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused on analyzing the efficacy and … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook

Posted on May 14, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit

Posted on May 11, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin

Posted on May 10, 2021 by MissionIR

During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial

Posted on April 22, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

Posted on April 16, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

Posted on April 8, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial

Posted on April 7, 2021 by MissionIR

Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed A recent study by the Washington University School of Medicine found … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021

Posted on March 29, 2021 by MissionIR

GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021 The company is continuing … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials

Posted on March 25, 2021 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment